Clinical Trial Update: Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating oxycodone/naloxone prolonged release versus placebo for improving symptoms of moderate to severe restless legs syndrome with day…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Oxycodone/naloxone prolonged release (oxycodone/naloxone)

Snippet

Sponsor: Mundipharma Research GmbH & Co KG | Conditions: Moderate to Severe Idiopathic RLS With Daytime Symptoms | Phase 3 | Status: COMPLETED